Lantheus issues early results from F-18 flurpiridaz CAD trial

10/30/2013 | Business Wire

Lantheus Medical Imaging has released preliminary findings from Phase III clinical trials of F-18 flurpiridaz, a PET myocardial perfusion imaging agent for detection of heart disease. According to the results, PET MPI with F-18 flurpiridaz outperformed SPECT in terms of sensitivity and diagnostic accuracy but did not meet an endpoint associated with identifying healthy subjects.

View Full Article in:

Business Wire

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide